Press release

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing

Compass Therapeutics, Inc.November 13, 20243
Compass Therapeutics to Participate in Upcoming Investor Events

About this update from Compass Therapeutics, Inc.

BOSTON , Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2024 . Details are as follows: Stifel 2024 Healthcare Conference Location: New York, NY Date: Monday, November 18, 2024 Time: 3:00pm ET Webcast Link: https://wsw.com/webcast/stifel96/cmpx Jefferies London Healthcare Conference Location: London, UK Date: November 21, 2024 Time: 2:00-2:25 PM GMT Webcast Link: https://wsw.com/webcast/jeff315/cmpx Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts . For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com . Investor Contact [email protected] Media Contact Anna Gifford , Senior Manager of Communications [email protected] 617-500-8099 Source: Compass Therapeutics

View stock analysis, news, and events for Compass Therapeutics, Inc.

More from Compass Therapeutics, Inc.

All Compass Therapeutics, Inc. news →